This is a single-arm, multi-site, single-dose, Phase 3 study in approximately 18 participants less than or equal to (<=) 50 years of age with transfusion-dependent β-thalassemia (tdt), who have a β0 β0, β0 ivs-i-110, or ivs-i-110 ivs-i-110 genotype. the study will evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation (hsct) using lentiglobin bb305 drug product.>

View full study on ClinicalTrials.gov